Children and young adults with epilepsy may qualify for investigational studies of cannabidiol, an ingredient in marijuana.
The state Health Department announced Wednesday that studies of cannabidiol are slated to begin in New York. For those of you who don’t know, cannabidiol is one of at least 85 active cannabinoids identified in cannabis. It is a major phytocannabinoid, accounting for up to 40% of the plant’s extract. Patients age 1-21, who are resistant to other medicines and treatments, may qualify for the study which will be held in five different locations: three in New York City, one in Rochester, and one in Buffalo. “These studies will give patients in New York State who are not responding to conventional anti-epileptic therapy access to a drug that has shown promise in previous expanded access studies,” said state Health Commissioner Howard Zucker.
Cannabidiol has been seen to be an anticonvulsant in animals in a variety of diverse tests by scientists, but controlled studies in humans are lacking tremendously. With the lack of study, it’s really difficult to testify on it’s behalf until more hypotheses of the ingredient are proven and backed by experimental evidence. Initial enrollment will begin in the next few months, and possibly will continue and expand to other states based on the successfulness of the study. Children with epilepsy already qualify to get medical marijuana under the state’s nascent program, but according to the state Health Department, the specific product being studied Epidiolex is only available through the study. The goal is for participants in the study to possibly benefit from the particular strain of cannabidiol being investigated. Children and young adults must be referred by their neurologists for consideration, and as participants, the study will last for a year.
If you or a loved one are considering such alternatives, the studies will take place at these locations: Montefiore Medical Center in the Bronx, the University of Buffalo/Women & Children’s Hospital of Buffalo, New York Langone Medical Center, Mount Sinai Beth Israel in Manhattan, and the University of Rochester Medical Center. Hopefully more and more studies like this one will emerge and be successful so we can finally put an end to the epidemics especially in children in a holistic manner. The reality of relying on prescription drugs is too heavy a weight to bear once started, why should we subject our future generations to such dependency.
For the latest clinical information related Cannabis and epilepsy visit UnitedPatientsGroup.com